Table 1 Clinical actionability of pancreatic cancer*.

From: Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

Clinical actionability type Total cases Fraction of cases (%; n=101)
FDA-approved therapy (pancreatic cancer) 0 0
FDA-approved therapy (another indication) 6 6
Published trial (pancreatic cancer) 0 0
Published trial (another indication) 27 27
Active trial (pancreatic cancer) 17 (96) 17 (95)
All types combined 38 (98) 38 (97)
  1. FDA, Food and Drug Administration.
  2. *Figures in parentheses include patients with tumours that harbour alterations in KRAS and TP53 as these may be eligible for current clinical trials.